Human Health Innovation

Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation.

human scientist
Drug Discovery Human Health

Research and Development Pipeline

With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we continue our track record of long-term innovation-led performance.

“Rapid progress towards clinical candidates”
The rise of drug-resistant pathogens is a real threat.
Human Health Innovation

“Rapid progress towards clinical candidates”

Michel Pairet, Member of the Board of Managing Directors, explains why Boehringer Ingelheim expands its commitment to fighting drug resistant infections with a new joint venture.

Related Press Releases

investiganol lungs
May 13,2022

Investigational treatment slowed lung function decline in IPF

Read more
AAD press release supporting image_resized
March 28,2022

New spesolimab data show significant improvement in GPP flares

Read more
220316_EMPA-KIDNEY_Early-Stop_0
March 22,2022

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Read more
EMA_website_teaser_card_16_9 (1)
March 07,2022

Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction

Read more
786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01
February 24, 2022

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

Read more